Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors

NCT04234113 is registered in ClinicalTrials.gov with SOTIO Biotech AG as lead sponsor.

NCT NCT04234113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04234113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Lead sponsor
SOTIO Biotech AG
Phase
Phase 1
Overall status
Terminated
Start date
June 13, 2019
Completion date
November 27, 2024
Enrollment
115 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, biliary tract cancer, bladder cancer, cervical cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, merkel cell carcinoma, mesothelioma, microsatellite instability high, non small cell lung cancer, ovarian cancer, renal cell carcinoma, skin squamous cell carcinoma, small-cell lung cancer, thymic cancer, thyroid cancer, triple negative breast cancer